EP4103208A4 - Rekombinante therapeutische interventionen für krebs - Google Patents

Rekombinante therapeutische interventionen für krebs Download PDF

Info

Publication number
EP4103208A4
EP4103208A4 EP21754580.5A EP21754580A EP4103208A4 EP 4103208 A4 EP4103208 A4 EP 4103208A4 EP 21754580 A EP21754580 A EP 21754580A EP 4103208 A4 EP4103208 A4 EP 4103208A4
Authority
EP
European Patent Office
Prior art keywords
against cancer
therapeutic interventions
recombinant therapeutic
interventions against
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP21754580.5A
Other languages
English (en)
French (fr)
Other versions
EP4103208A1 (de
Inventor
William R. Bishai
Trinity J. BIVALACQUA
Alok Singh
Monali PRAHARAJ
Takahiro Yoshida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of EP4103208A1 publication Critical patent/EP4103208A1/de
Publication of EP4103208A4 publication Critical patent/EP4103208A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP21754580.5A 2020-02-13 2021-02-12 Rekombinante therapeutische interventionen für krebs Withdrawn EP4103208A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202016790161A 2020-02-13 2020-02-13
PCT/US2021/018007 WO2021163602A1 (en) 2020-02-13 2021-02-12 Recombinant therapeutic interventions for cancer

Publications (2)

Publication Number Publication Date
EP4103208A1 EP4103208A1 (de) 2022-12-21
EP4103208A4 true EP4103208A4 (de) 2024-05-08

Family

ID=77292873

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21754580.5A Withdrawn EP4103208A4 (de) 2020-02-13 2021-02-12 Rekombinante therapeutische interventionen für krebs

Country Status (6)

Country Link
EP (1) EP4103208A4 (de)
JP (1) JP2023514553A (de)
CN (1) CN115443143A (de)
AU (1) AU2021220986A1 (de)
CA (1) CA3167223A1 (de)
WO (1) WO2021163602A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12359209B2 (en) 2018-04-17 2025-07-15 The Johns Hopkins Unversity Recombinant therapeutic interventions for cancer
CA3194581A1 (en) * 2020-10-01 2022-04-07 Alok Singh Bcg based vaccine compositions and methods of use thereof
CN115337393A (zh) * 2022-07-07 2022-11-15 中国人民解放军空军军医大学 一种过表达结核分枝杆菌c-di-AMP合成酶的重组卡介苗rBCG-DisA的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019014391A1 (en) * 2017-07-12 2019-01-17 Synlogic Operating Company, Inc. MICROORGANISMS PROGRAMMED TO PRODUCE IMMUNOMODULATORS AND ANTICANCER THERAPEUTIC AGENTS IN TUMOR CELLS
WO2019203965A1 (en) * 2018-04-17 2019-10-24 The Johns Hopkins University Recombinant therapeutic interventions for cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2620159A1 (de) * 2012-01-24 2013-07-31 Institut Pasteur Verbesserte Krebsbehandlung durch Immuntherapie mit BCG- oder antigenetisch ähnlichen nicht-pathogenen Mykobakterien
WO2018112360A1 (en) * 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Combination therapies for treating cancer
BR112019013863A2 (pt) * 2017-01-06 2020-03-03 Synlogic Operating Company, Inc. Micro-organismos programados para produzir moduladores imunes e terapêuticos anticâncer em células tumorais
WO2020002905A1 (en) * 2018-06-25 2020-01-02 Immodulon Therapeutics Limited Cancer therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019014391A1 (en) * 2017-07-12 2019-01-17 Synlogic Operating Company, Inc. MICROORGANISMS PROGRAMMED TO PRODUCE IMMUNOMODULATORS AND ANTICANCER THERAPEUTIC AGENTS IN TUMOR CELLS
WO2019203965A1 (en) * 2018-04-17 2019-10-24 The Johns Hopkins University Recombinant therapeutic interventions for cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2021163602A1 *

Also Published As

Publication number Publication date
WO2021163602A1 (en) 2021-08-19
EP4103208A1 (de) 2022-12-21
CA3167223A1 (en) 2021-08-19
CN115443143A (zh) 2022-12-06
AU2021220986A1 (en) 2022-09-01
JP2023514553A (ja) 2023-04-06

Similar Documents

Publication Publication Date Title
DK3947375T3 (da) Imidazolonylquinolinforbindelser og terapeutiske anvendelser deraf
IL291486A (en) Therapeutic conjugates
DK3768830T5 (da) Cancerterapi
EP3750553A4 (de) Therapeutikum für psoriasis
EP4103208A4 (de) Rekombinante therapeutische interventionen für krebs
EP3781184A4 (de) Rekombinante therapeutische interventionen für krebs
IL291170A (en) Treatment of hr deficient cancer
IL270697A (en) Therapeutic apoptotic cells for cancer therapy
EP4308121A4 (de) Therapeutische konjugate
EP4013440A4 (de) Therapeutische peptide
GB201905780D0 (en) Cancer therapy
EP3927328A4 (de) Inhalierbares therapeutikum
EP3919072A4 (de) Herstellung eines krebsvakzins
EP4122465A4 (de) Brustkrebstherapeutikum
EP4025203A4 (de) Krebsbehandlung
IL304436A (en) Cancer treatment
GB202006960D0 (en) Therapeutic
MA54932A (fr) Traitement contre le cancer
EP4188431A4 (de) Kombinationstherapie gegen krebs
EP4401721A4 (de) Krebsbehandlung
IL312025A (en) Therapeutic rna for lung cancer
IL312249A (en) Combination therapy for treating lung cancer
EP4083213A4 (de) Arzneimittel zur krebstherapie
EP3960242A4 (de) Konjugat und krebstherapeutikum
EP3897669A4 (de) Verfahren und zusammensetzungen im zusammenhang mit therapeutischen peptiden zur krebstherapie

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220830

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230516

A4 Supplementary search report drawn up and despatched

Effective date: 20240410

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/74 20060101ALI20240404BHEP

Ipc: A61P 35/00 20060101ALI20240404BHEP

Ipc: A61K 39/00 20060101ALI20240404BHEP

Ipc: C12N 15/70 20060101ALI20240404BHEP

Ipc: A61K 39/39 20060101ALI20240404BHEP

Ipc: A61K 39/04 20060101ALI20240404BHEP

Ipc: A61K 35/74 20150101AFI20240404BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20241031